Alfacalcidol
Alfacalcidol structure
|
Common Name | Alfacalcidol | ||
|---|---|---|---|---|
| CAS Number | 41294-56-8 | Molecular Weight | 400.637 | |
| Density | 1.0±0.1 g/cm3 | Boiling Point | 531.5±50.0 °C at 760 mmHg | |
| Molecular Formula | C27H44O2 | Melting Point | 134-136°C | |
| MSDS | Chinese USA | Flash Point | 222.6±24.7 °C | |
| Symbol |
GHS06 |
Signal Word | Danger | |
|
[Combination of alendronate plus alfacalcidol in the treatment of osteoporosis. Rationale, preclinical data and clinical evidence].
MMW Fortschr. Med. 154 Suppl 1 , 10-21, (2012) The therapeutic strategy for the reduction of fracture risk in osteoporosis should not only aim to increase bone strength, but should also improve muscle function and reduce falls without increasing the risk of significant side effects. Since 2008 a combinati... |
|
|
Active vitamin D analogs, maxacalcitol and alfacalcidol, as maintenance therapy for mild secondary hyperparathyroidism in hemodialysis patients - a randomized study.
Int. J. Clin. Pharmacol. Ther. 52(5) , 360-8, (2014) The present randomized study was designed to compare the efficacy between two active vitamin D analogs, alfacalcidol (ACD) and maxacalcitol (OCT), for the management of mild secondary hyperparathyroidism (SHPT) in dialysis patients.SHPT in all 32 patients ana... |
|
|
Rationale for treatment of involutional osteoporosis in women and for prevention and treatment of corticosteroid-induced osteoporosis with alfacalcidol.
Calcif. Tissue Int. 65(4) , 317-27, (1999) Increased cytokine release and increased activity of osteoclasts (reduced osteoclast apoptosis) due to a fall in estrogen is of causal significance in postmenopausal bone loss as well as malfunction of the vitamin D activation and concomitant calcium (Ca) mal... |
|
|
Alfacalcidol enhances collagen quality in ovariectomized rat bones.
J. Orthop. Res. 32(8) , 1030-6, (2014) The aim of this study was to investigate the effects of alfacalcidol (1α(OH)D3 : ALF) on bone collagen employing an ovariectomized rat model. Thirty-five 16-week-old female Sprague-Dawley rats were divided into five groups: SHAM (sham-operated + vehicle), OVX... |
|
|
Is there a differential response to alfacalcidol and vitamin D in the treatment of osteoporosis?
Calcif. Tissue Int. 60(1) , 111-4, (1997) : There is a decline in serum 25 hydroxyvitamin D (25OHD), 1,25 dihydroxyvitamin D (1,25(OH)2D), and calcium absorption with advancing age, which may lead to secondary hyperparathyroidism and bone loss. Studies show a relationship between serum 25OHD and bone... |
|
|
A new look at the most successful prodrugs for active vitamin D (D hormone): alfacalcidol and doxercalciferol.
Molecules 14(10) , 3869-80, (2009) Alfacalcidol (1alpha-hydroxyvitamin D(3)) has been widely used since 1981 as a prodrug for calcitriol (1alpha,25-dihydroxyvitamin D(3)) in the treatment of hypocalcemia, chronic renal failure, hypoparathyroidism and osteoporosis. More recently, doxercalcifero... |
|
|
D-hormone analog alfacalcidol: an update on its role in post-menopausal osteoporosis and rheumatoid arthritis management.
Aging Clin. Exp. Res. 17(2) , 133-42, (2005) Alfacalcidol (1-alpha-hydroxyvitamin D3) is a non-endogenous analog of vitamin D which can bypass the renal and intestinal regulatory mechanisms that control the production of calcitriol (1,25-hydroxyvitamin D3, the active form of vitamin D, D-Hormone). Alfac... |
|
|
Relationship between the effect of eldecalcitol and serum 25(OH)D level.
J. Steroid Biochem. Mol. Biol. 144 Pt A , 124-7, (2014) In previous studies, we demonstrated that 12-month treatment with 0.75μg/day eldecalcitol increased bone mineral density in osteoporotic patients regardless of serum 25-hydroxyvitamin D (25(OH)D) level, and in a 3-year randomized double-blind clinical trial, ... |
|
|
Eldecalcitol improves mechanical strength of cortical bones by stimulating the periosteal bone formation in the senescence-accelerated SAM/P6 mice - a comparison with alfacalcidol.
J. Steroid Biochem. Mol. Biol. 144 Pt A , 119-23, (2014) Eldecalcitol (ELD), a 2β-hydroxypropyloxy derivative of 1α,25(OH)2D3, is a potent inhibitor of bone resorption that has demonstrated a greater effect at reducing the risk of fracture in osteoporotic patients than alfacalcidol (ALF). In the present study, we u... |
|
|
Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol.
Rheumatol. Int. 28(2) , 103-11, (2007) While in other chronic diseases combined treatment regimens are the rule there is a lack of reported experience or study data on combining different specific drugs to treat osteoporosis. Significant differences in the mode of action (MOA) of the substances to... |